Determination of the ex vivo rates of human immunodeficiency virus type 1 reverse transcription by using novel strand-specific amplification analysis.
about
HIV-1 reverse transcriptionHIV-1 polymerase inhibition by nucleoside analogs: cellular- and kinetic parameters of efficacy, susceptibility and resistance selectionAPOBEC3F and APOBEC3G inhibit HIV-1 DNA integration by different mechanisms.Delaying reverse transcription does not increase sensitivity of HIV-1 to human TRIM5α.Role of HIV-1 nucleocapsid protein in HIV-1 reverse transcription.A cell-based strategy to assess intrinsic inhibition efficiencies of HIV-1 reverse transcriptase inhibitors.Reverse Transcriptase and Cellular Factors: Regulators of HIV-1 Reverse Transcription.Nucleocapsid protein function in early infection processes.The remarkable frequency of human immunodeficiency virus type 1 genetic recombinationNuclear import of APOBEC3F-labeled HIV-1 preintegration complexes.The importance of becoming double-stranded: Innate immunity and the kinetic model of HIV-1 central plus strand synthesis.Quantitative microscopy of functional HIV post-entry complexes reveals association of replication with the viral capsidStrain-specific differences in the impact of human TRIM5alpha, different TRIM5alpha alleles, and the inhibition of capsid-cyclophilin A interactions on the infectivity of HIV-1.Full genome ultra-deep pyrosequencing associates G-to-A hypermutation of the hepatitis B virus genome with the natural progression of hepatitis B.Clinical use of lentiviral vectors.Recombination is required for efficient HIV-1 replication and the maintenance of viral genome integrity
P2860
Q27023387-15AB503C-1D45-4A75-8BFB-A0CD12A84E54Q28478993-3B236B8F-AF2B-4E1A-9EF9-C2DFB06A82EDQ33826968-DEA425C3-3B35-4CED-B82C-E5DCEFA8E413Q34548171-103BA263-159B-437B-8515-13314F94AA79Q34775658-B4C6B4FA-EEF5-4E19-9ED6-3CF0169A0B64Q35105821-EBC437EF-1D8F-4E5C-8657-8B34F9AB73C6Q35260021-66178D62-7B4E-4DBE-9890-905D05C061D1Q37086413-AC863B1F-D400-489A-9E48-89C695963BEDQ37333701-CCC387B6-7E55-42FA-9ACA-FC1CB71A3DFFQ37377405-A8B3B0A7-4047-4B30-81C7-B0722803F486Q38096531-55FF975D-7C7E-435D-8DBF-F5093464CB4DQ38927692-5D4890F3-7D1F-4329-BD42-0CF1BE2E34DFQ41824328-C097BA5F-E3AE-47D4-8B8C-3F47C7602D4DQ42251194-96FDFFE4-BD7C-49F7-93C7-929E36629CAFQ52589095-A64737FB-98D7-4F8D-85F7-55899578CB64Q57281460-F1D676BD-F77C-4EF8-80A0-626C67A7452C
P2860
Determination of the ex vivo rates of human immunodeficiency virus type 1 reverse transcription by using novel strand-specific amplification analysis.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Determination of the ex vivo r ...... ecific amplification analysis.
@ast
Determination of the ex vivo r ...... ecific amplification analysis.
@en
type
label
Determination of the ex vivo r ...... ecific amplification analysis.
@ast
Determination of the ex vivo r ...... ecific amplification analysis.
@en
prefLabel
Determination of the ex vivo r ...... ecific amplification analysis.
@ast
Determination of the ex vivo r ...... ecific amplification analysis.
@en
P2093
P2860
P356
P1433
P1476
Determination of the ex vivo r ...... pecific amplification analysis
@en
P2093
David C Thomas
Galina N Nikolenko
Wei-Shau Hu
Yegor A Voronin
P2860
P304
P356
10.1128/JVI.02471-06
P407
P577
2007-02-21T00:00:00Z